CME/CE - Prova Education

Episodes 1-16 of 254

Treating At-Risk MASH: What Are You Waiting For?
Treating At-Risk MASH: What Are You Waiting For?
CME/CE Live Broadcast
Treating At-Risk MASH: What Are You Waiting For?
January 11, 2025
12:00 PM - 01:00 PM MST
1.00 credit Learn more
CME/CE Meeting
Treating At-Risk MASH: What Are You Waiting For?
January 11, 2025
Park City, Utah
1.00 credit Learn more
CME/CE Meeting
Personalizing Care Within the Advanced RCC Treatment Paradigm: A Fireside Chat and Roundtable Symposium
February 13, 2025
San Francisco, California
1.50 credits Learn more
Personalizing Care Within the Advanced RCC Treatment Paradigm: A Fireside Chat and Roundtable Symposium
Personalizing Care Within the Advanced RCC Treatment Paradigm: A Fireside Chat and Roundtable Symposium
CME/CE Live Broadcast
Personalizing Care Within the Advanced RCC Treatment Paradigm: A Fireside Chat and Roundtable Symposium
February 13, 2025
07:30 PM - 09:00 PM PT
1.50 credits Learn more
CME/CE Meeting
Think Tank Live: Collaborative Insights to Solve the Puzzle of Bladder Cancer
February 14, 2025
San Francisco, California
1.50 credits Learn more
Think Tank Live: Collaborative Insights to Solve the Puzzle of Bladder Cancer
Think Tank Live: Collaborative Insights to Solve the Puzzle of Bladder Cancer
CME/CE Live Broadcast
Think Tank Live: Collaborative Insights to Solve the Puzzle of Bladder Cancer
February 14, 2025
06:00 PM - 08:00 PM PST
1.50 credits Learn more
Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
MinuteCE®
Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
1.00 program credit
- Susana Campos, MD, MPH
- Ritu Salani, MD, MBA
1.00 program credit
Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
MinuteCE®
Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
0.75 program credits
- Rana McKay, MD
0.75 program credits
Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
MinuteCE®
Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
1.00 program credit
- Susana Campos, MD, MPH
- Nicoletta Colombo, MD
1.00 program credit
First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
MinuteCE®
First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
1.00 program credit
- Nicoletta Colombo, MD
- Ritu Salani, MD, MBA
1.00 program credit
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
MinuteCE®
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
1.00 program credit
- Ritu Salani, MD, MBA
- Nicoletta Colombo, MD
1.00 program credit
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
MinuteCE®
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
1.00 program credit
- Susana Campos, MD, MPH
1.00 program credit
Best Practices in Shared Decision Making: Selection of the Optimal ADT Regimen in mHSPC Based on Patient Preferences
Best Practices in Shared Decision Making: Selection of the Optimal ADT Regimen in mHSPC Based on Patient Preferences
MinuteCE®
Best Practices in Shared Decision Making: Selection of the Optimal ADT Regimen in mHSPC Based on Patient Preferences
0.75 program credits
- Rana McKay, MD
0.75 program credits
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Genitourinary Cancers
1.25 credits 10 episodes
- Ignacio Duran, MD
- Wenxin Xu, MD
- Sandy Srinivas, MD
1.25 credits 10 episodes
Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
MinuteCE®
Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
1.00 program credit
- Ritu Salani, MD, MBA
- Nicoletta Colombo, MD
1.00 program credit
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
MinuteCE®
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
1.00 program credit
- Nicoletta Colombo, MD
- Susana Campos, MD, MPH
1.00 program credit

Prev
1
2
3
…
15
16
Next

1/6